This is a routine procedural discovery order with no immediate stock impact. Monitor for substantive rulings on the false advertising claims or any settlement developments, but no trader action warranted.
Price Chart
Executive Summary
A magistrate judge in the Northern District of California granted in part and denied in part a discovery motion in Eli Lilly's false advertising suit against Adonis Health (Henry Meds) over compounded tirzepatide. The court ordered Lilly to produce financial records and safety data but denied discovery of shortage-period documents. This is a routine discovery ruling with no material financial impact on Lilly.
Court Ruling Details
Key Facts
- Lilly is suing Adonis Health (Henry Meds) for false advertising related to compounded tirzepatide (Mounjaro/Zepbound).
- Court ordered Lilly to produce financial records of tirzepatide sales (relevant to standing) and adverse event/safety data (minimally probative of medical necessity).
- Court denied discovery of shortage-period documents because Lilly does not seek damages from that period.
- Ruling is a discovery order (ECF No. 97), not a final judgment or merits determination.
- No damages awarded, no injunction issued, no liability finding.
Financial Impact
No monetary award or financial exposure stated in the ruling.
Risk Factors
- Discovery of financial and safety data could strengthen Henry Meds' defense, but no material risk to Lilly's business.
- Case remains active; an adverse final judgment on the merits could carry reputational or injunctive risk, but that is distant.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-b9031acc84-LLY |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | Press Release | $1,115.70 $1,152.93 | ▲ +3.34% | ▲ +3.56% | $1,145.86 (+2.70%) |
Sep 8, 2026 24d ago | Court Ruling | $1,123.91 $1,138.28 | ▲ +1.28% | ▲ +1.94% | $1,145.86 (+1.95%) |
Aug 18, 2026 6w ago | Insider Cluster | $1,225.73 $1,233.66 | ▲ +0.65% | ▲ +0.85% | $1,145.86 (−6.52%) |
Aug 11, 2026 7w ago | Insider Cluster | $1,215.02 $1,225.73 | ▲ +0.88% | ▲ +1.29% | $1,145.86 (−5.69%) |
Aug 7, 2026 8w ago | Court Ruling | $1,185.71 $1,180.16 | ▼ −0.47% | ▼ −0.87% | $1,145.86 (−3.36%) |
Aug 5, 2026 8w ago | 8-K | $1,169.86 $1,220.28 | ▲ +4.31% | ▲ +3.96% | $1,145.86 (−2.05%) |
Aug 4, 2026 8w ago | Court Ruling | $1,115.68 $1,215.02 | ▲ +8.90% | ▲ +9.00% | $1,145.86 (+2.70%) |
Jul 31, 2026 9w ago | Court Ruling | $1,148.84 $1,185.71 | ▼ −3.21% | ▲ +0.30% | $1,145.86 (+0.26%) |
Jul 30, 2026 9w ago | Court Ruling | $1,154.97 $1,191.94 | ▲ +3.20% | ▼ −0.42% | $1,145.86 (−0.79%) |
Jul 22, 2026 10w ago | Press Release | $1,163.01 $1,210.02 | ▲ +4.04% | ▲ +6.44% | $1,145.86 (−1.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access